The Food and Drug Administration user fee renewal bill is now the law of the land.
On Monday, President Barack Obama signed into law S.3187, or the FDA Safety and Innovation Act, which reauthorizes the FDA's powers to collect some $6.4 billion in user fees from medical device manufacturers and pharmaceutical companies to help offset the costs of application reviews and inspections.
The new law, which enjoyed hearty bipartisan support and sailed through both houses of Congress, increases the amount of money FDA can raise from companies and, for the first time, also applies to generic drug and biologics manufacturers.
The legislation also includes some tweaks pushed for by device companies. For instance, the FDA must measure the time it spends reaching a decision on a device submission by the total time used, rather than in "FDA days."
Significantly, too, it requires the FDA to release unique device identifier rules -- a new system for tracking medical devices in the supply chain -- by the end of the year. This point, however, is moot: the FDA released the rules, presumably not coincidentally, last week.
ITS ABOUT TIME THSE BILLION DOLLARS PROFIT COMPANIES PAY THE TAX
July 11, 2012 06:55
HE DAYS OF R%D DEVELOPMENT COSTS(THAT ARE OVERINFLATED FOR TAX BREAKS)SHOULD COME TO AN END. THE FDA NEEDS TO STAY ON THESE COMPANIES AND HUGE FINES FOR THE GREEDY PROFIT THEY MAKE
(2)
(3)
Ramon Cervantes
ITS ABOUT TIME THSE BILLION DOLLARS PROFIT COMPANIES PAY THE TAX
July 11, 2012 06:55
HE DAYS OF R%D DEVELOPMENT COSTS(THAT ARE OVERINFLATED FOR TAX BREAKS)SHOULD COME TO AN END. THE FDA NEEDS TO STAY ON THESE COMPANIES AND HUGE FINES FOR THE GREEDY PROFIT THEY MAKE
to rate and post a comment